Leonberg-Yoo Amanda K, Wang Weiling, Weiner Daniel E, Lacson Eduardo
Renal-Electrolyte and Hypertension Division, Department of Medicine, Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, USA.
Fresenius Medical Care, North America, Waltham, Massachusetts, USA.
Hemodial Int. 2019 Jan;23(1):93-100. doi: 10.1111/hdi.12694. Epub 2019 Feb 14.
Hemodialysis (HD) patients are hospitalized nearly twice yearly, and 35% of these patients are rehospitalized within 30-days postdischarge. We hypothesized that monitored oral nutritional supplementation (ONS) during HD treatment may decrease readmissions.
A cohort of maintenance HD patients, treated at a large dialysis organization, who were hospitalized with a postdischarge albumin of ≤3.5 g/dL, without documented ONS use 90 days prior to the index hospitalization were identified. Individuals who received monitored intradialytic ONS postdischarge were compared to those without receipt of ONS. The outcome of interest was 30-day hospital readmissions. Logistic regression was used to assess the association between ONS receipt and 30-day readmission events, with adjustment for case-mix and laboratory variables.
Of 5479 eligible patients, ONS was prescribed to 1420 individuals. Mean age was 64.6 ± 14.1 (SD) years; median dialysis vintage was 3.9 years. There were 274 (19%) readmissions among ONS recipients vs. 1571 (38.7%) among controls during the 30-day follow-up period. Individuals who did not receive ONS had increased odds of readmission [OR 2.26 (95% CI 1.02, 2.53)] in 30 days, as compared to those who did receive ONS postdischarge. In sensitivity analyses using a propensity score matched cohort, the odds ratio of readmissions within 30 days postdischarge was 1.71 (95% CI: 1.42, 2.07) for individuals who did not receive ONS as compared to those who received ONS.
Consumption of ONS during HD sessions is associated with reduced hospital readmission rates among in-center maintenance HD with severe hypoalbuminemia at 30 days post-hospital discharge.
血液透析(HD)患者每年住院近两次,其中35%的患者在出院后30天内再次住院。我们假设在HD治疗期间进行监测的口服营养补充(ONS)可能会减少再入院率。
在一个大型透析机构接受治疗的维持性HD患者队列中,确定那些出院时白蛋白≤3.5g/dL且在本次住院前90天内未记录使用ONS的患者。将出院后接受监测的透析期间ONS的个体与未接受ONS的个体进行比较。感兴趣的结果是30天内再次住院。使用逻辑回归评估ONS接受情况与30天再入院事件之间的关联,并对病例组合和实验室变量进行调整。
在5479名符合条件的患者中,1420人被开具了ONS。平均年龄为64.6±14.1(标准差)岁;透析中位时间为3.9年。在30天的随访期内,ONS接受者中有274人(19%)再次住院,而对照组中有1571人(38.7%)。与出院后接受ONS的个体相比,未接受ONS的个体在30天内再次住院的几率增加[比值比2.26(95%置信区间1.02,2.53)]。在使用倾向评分匹配队列的敏感性分析中,与接受ONS的个体相比,未接受ONS的个体在出院后30天内再次住院的比值比为1.71(95%置信区间:1.42,2.07)。
在HD治疗期间食用ONS与中心维持性HD患者出院后30天严重低白蛋白血症的医院再入院率降低有关。